Thursday, October 9, 2025

Latest

Biopharmaceutical Firm Candel Therapeutics Prices Downsized US$72 Million IPO

Late clinical stage biopharmaceutical company Candel Therapeutics Inc. (Nasdaq: CADL) started publicly trading on the Nasdaq Global Market today under the symbol “CADL”. The firm’s initial public offering is looking to raise US$72.0 million and is expected to close on July 29, 2021.

The offering will be conducted through the issuance of 9,000,000 common shares selling at US$8.00 per share. This is an adjustment from the company’s original plan to issue 6.1 million shares with share price expectations between US$13.00 and US$15.00.

The company granted a 30-day over-allotment option to purchase additional 1,350,000 common shares at the same IPO price, potentially bringing proceeds up to US$82.8 million. Jefferies, Credit Suisse, BMO Capital Markets, and UBS Investment Bank are all acting as joint bookrunners for the said offering.

The Massachusetts-based biotech firm is in the business of developing novel oncolytic viral immunotherapies to treat patients with cancer, inducing “immunogenic cell death in cancer cells at the site of injection”. Currently, Candel Therapeutics has immunotherapy platforms in its portfolio –the lead adenovirus platform product candidate CAN-2409 and the lead HSV platform product candidate CAN-3310.


Information for this briefing was found via Sedar and Candel Therapeutics. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Fortune Bay: The Potential Billion Dollar Project

Japan Gold Enters New Chapter as Barrick Alliance Concludes – John Proust

Barrick Mining’s “Company Defining [Gold] Discovery”

Recommended

Nord Precious Metals Produces High Grade Silver Concentrate From Tailings

ESGold Secures $9 Million In Non-Dilutive Funding From Ocean Partners

Related News

Electric Vehicle Maker Rivian Prices Upsized US$11.9 Billion IPO

Start-up electric vehicle maker Rivian Automotive, Inc. (Nasdaq: RIVN) started trading on the Nasdaq Global...

Wednesday, November 10, 2021, 02:17:00 PM

Biopharmaceutical Firm DICE Therapeutics Prices Upsized US$204 Million IPO

Biopharmaceutical company DICE Therapeutics, Inc. (Nasdaq: DICE) started publicly trading on the Nasdaq Global Market...

Thursday, September 16, 2021, 11:08:00 AM

SPAC Portage Fintech Acquisition Upsizes IPO To US$240 Million

Special purpose acquisition company Portage Fintech Acquisition Corporation (Nasdaq: PFTAU) announced Tuesday that it is...

Wednesday, July 21, 2021, 12:03:00 PM

SEMRush: Analyzing Data To Extract Consumer Insights – The Daily Dive

Starting off this week on the Daily Dive is that of Eugene Levin, chief strategy...

Monday, May 10, 2021, 01:30:00 PM

Birkenstock Prices IPO At $46 Per Share, Aims To Raise $1.48 Billion

Birkenstock Holdings (NYSE: BIRK) has revealed the pricing details of its initial public offering (IPO),...

Wednesday, October 11, 2023, 09:06:07 AM